FDA approves Regeneron's Pasatru for treatment of FOP.
The U.S. FDA approved Regeneron's drug Pasatru (garetosmab) to treat fibrodysplasia ossificans progressiva (FOP). FOP is an ultra-rare disease that causes soft tissue to turn into bone. The approval is a delivered result, but the drug's impact on patients and its use have yet to be observed.
Why it matters
This provides patients with this debilitating genetic disease a new approved therapy, addressing a previous lack of targeted medical options.
CHECKED · 1 SOURCE · UNCORROBORATED
← All news